Sign up online today & collaborate
or click here to find out more
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'), announces it has entered into an equity and revenue sharing agreement (the 'Revenue Share Agreement') with the Wellcome Trust, covering potential future revenues generated by ridinilazole, its highly selective, novel-class antibiotic for the treatment of CDI.
The Revenue Share Agreement is a follow-on to the October 2012 Translational Award Funding Agreement with the Wellcome Trust ('TA Agreement'), which provided funding for the now concluded Phase 1 and Phase 2 clinical trials for ridinilazole. The commercial terms in the Revenue Share Agreement summarised below replace those detailed in the TA Agreement. Ridinilazole is currently being prepared to enter Phase 3 clinical trials in the first half of 2018.
"The Wellcome Trust has played a crucial role in supporting the development of our CDI programme, having provided funding to advance ridinilazole from the early stages of discovery through to generating clinical proof of concept in patients with CDI," commented Dr David Roblin, Chief Operating Officer and Medical Officer at Summit."We believe ridinilazole is a precision antibiotic that has the potential to become a front-line therapy for CDI and to deliver real patient benefit. We look forward to commencing our Phase 3 clinical programme in the first half of 2018."
Under the Revenue Share Agreement, the Wellcome Trust is eligible to receive the following payments if commercialisation of ridinilazole is undertaken by a third-party:
If Summit undertakes the commercialisation of ridinilazole, Wellcome Trust is eligible to receive:
In addition, under the Revenue Share Agreement, the Wellcome Trust agreed to terminate all of its rights under the TA Agreement to develop or commercialise ridinilazole or the associated intellectual property in the event that Summit was not developing or commercialising ridinilazole.
Separately, the TA Agreement has been novated from Summit Therapeutics plc to its wholly owned subsidiary company, Summit (Oxford) Limited. The Revenue Sharing Agreement will, unless earlier terminated, expire upon the later of: the expiration of the last patent or patent application covering ridinilazole; the expiration of any agreement or payment obligations entered into by the Company with a third party relating to the commercialisation of ridinilazole; and the expiration of any payment obligations owed to the Wellcome Trust relating to the commercialisation of ridinilazole.
A Form 6-K has been filed with the US Securities and Exchange Commission ('SEC') that contains additional information about the terms of the Revenue Share Agreement with the Wellcome Trust. A copy of this Form 6-K is available to download either from the Investors section of the Company website at www.summitplc.com or from the SEC website at www.sec.gov.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).